Compare ENVX & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENVX | NEO |
|---|---|---|
| Founded | 2006 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Precision Instruments |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2020 | 2008 |
| Metric | ENVX | NEO |
|---|---|---|
| Price | $4.88 | $8.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $14.56 | $11.14 |
| AVG Volume (30 Days) | ★ 5.5M | 2.0M |
| Earning Date | 05-21-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,821,000.00 | N/A |
| Revenue This Year | $40.85 | $10.63 |
| Revenue Next Year | $236.84 | $9.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 37.91 | N/A |
| 52 Week Low | $4.84 | $4.72 |
| 52 Week High | $16.49 | $13.74 |
| Indicator | ENVX | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 30.07 | 26.03 |
| Support Level | N/A | $7.20 |
| Resistance Level | $8.73 | $8.89 |
| Average True Range (ATR) | 0.37 | 0.68 |
| MACD | -0.05 | -0.09 |
| Stochastic Oscillator | 0.94 | 4.21 |
Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, the United States, Norway, Taiwan, and other regions.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.